A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs - The New York Times
archive.today webpage capture Saved from history←priornext→ 31 Aug 2026 19:46:29 UTC All snapshots from host www.nytimes.com WebpageScreenshot sharedownload .zipreport bug or abuseBuy me a coffee SKIP TO CONTENT SKIP TO SITE INDEX SECTION NAVIGATION Search LOG IN A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs Rasonque, the new pancreatic cancer treatment from Revolution Medicines, illustrates the huge inflation in cancer drug prices over the past two decades. Listen · 10:13 min Daraxonrasib, a newly approved treatment for pancreatic cancer made by Revolution Medicines. Credit... Kim Raff for The New York Times By Rebecca Robbins Aug. 31, 2026 Updated 12:43 p.m. ET See more of our coverage in your search results. Add The New York Times on Google Revolution Medicines set a sticker price of about $480,000 a year, or $663 a tablet, for its new pancreatic cancer drug — a cost that would have once been unthinkably high. Today, such prices are routine for cancer drugs. On